Mendus is dedicated to changing the course of cancer treatment by addressing tumor recurrence and improving survival outcomes for cancer patients, while preserving quality of life. We are leveraging our unparalleled expertise in allogeneic dendritic cell biology to develop an advanced clinical pipeline of novel, off-the-shelf, cell-based immunotherapies which combine clinical efficacy with a benign safety profile. Based in Sweden and The Netherlands, Mendus is publicly traded on the Nasdaq Stockholm under the ticker IMMU.ST.
| Website | https://mendus.com/ |
| Employees | 24 (0 on RocketReach) |
| Address | Västra Trädgårdsgatan 15, Stockholm, Stockholm County 11153, SE |
| Phone | +46 8 732 84 00 |
| Industry | Biotechnology Research |
| Keywords | Cancer Treatment, Cancer Survival, Quality Of Life, Immunotherapy, Cancer Research, Oncology, Clinical Trials, Cancer Care, Cell Therapy, Immunology, Precision Medicine, Drug Development, Biotechnology, Medical Research, Patient Care, Cancer Prevention, Healthcare |
| Competitors | Novartis, Merck & Co., Inc., Sanofi, AstraZeneca, Bristol Myers Squibb, Amgen, Regeneron, Gilead Sciences, アステラス製薬（株）, Receptos, a wholly-owned subsidiary of Celgene +43 more (view full list) |
Looking for a particular Mendus AB employee's phone or email?
Mendus AB Questions
Mendus AB is based in Stockholm, Stockholm County.
Related Companies
G2Crowd Trusted
300K+
Plugin Users
